Anthony Mirhaydari

InvestorPlace Market Strategist

Anthony Mirhaydari is founder of the Edge and Edge Pro investment advisory newsletters.

He is an independent investment columnist with work appearing at Investorplace, The Fiscal Times, CBS News MoneyWatch, MSN Money, Yahoo Finance, and Dow Jones MarketWatch. He started covering the markets and the economy in the media in 2008 in the midst of the greatest financial crisis in generations.

Previously, he was a senior research analyst with Markman Capital Insight, an advisory and money management firm, and a business consulting analyst with Moss Adams focusing on the financial-services industry.

Recent Articles

3 Reasons Why Apple Stock Is Getting Cored (AAPL)

By Anthony Mirhaydari, InvestorPlace Market Strategist Oct 2, 2015

The price action in Apple stock reveals underlying problems with this longtime big-tech sweetheart. Here are a few of the issues with AAPL.

Stocks Quiet Ahead of Jobs Report

By Anthony Mirhaydari, InvestorPlace Market Strategist Oct 1, 2015

Defensive sectors lagged, with utilities and telecom stocks putting in the worst performance, while strength in U.S. auto sales couldn’t stop the September ISM manufacturing activity index from slipping.

Stocks Rebound to End the Worst Quarter in Four Years

By Anthony Mirhaydari, InvestorPlace Market Strategist Sep 30, 2015

The markets rebounded Wednesday, putting (hopefully) a stop to the worst quarter in four years. But with the Fed rate hike still looming, don't expect a rally to last.

Stocks End Mixed as Junk Bonds Get Smashed

By Anthony Mirhaydari, InvestorPlace Market Strategist Sep 29, 2015

Even a behemoth like Apple (AAPL) isn't safe from the volatility of the markets. In the meantime, I suggest taking a defensive position, such as in the TVIX.

Wall Street Hit as the Dow Jones Tests 16,000

By Anthony Mirhaydari, InvestorPlace Market Strategist Sep 28, 2015

Stocks are still in the midst of their "hike or no hike" anxiety attack, while the weakness is backed up by government action against Big Pharma and disappointing economic data from China, sending the Dow Jones lower.